Nanfack Aubin J, Redd Andrew D, Bimela Jude S, Ncham Genesis, Achem Emmanuel, Banin Andrew N, Kirkpatrick Allison R, Porcella Stephen F, Agyingi Lucy A, Meli Josephine, Colizzi Vittorio, Nádas Arthur, Gorny Miroslaw K, Nyambi Phillipe N, Quinn Thomas C, Duerr Ralf
Department of Pathology, New York University School of Medicine, New York, New York, USA.
Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
J Clin Microbiol. 2017 Sep;55(9):2785-2800. doi: 10.1128/JCM.00634-17. Epub 2017 Jun 28.
The global intensification of antiretroviral therapy (ART) can lead to increased rates of HIV drug resistance (HIVDR) mutations in treated and also in ART-naive patients. ART-naive HIV-1-infected patients from Cameroon were subjected to a multimethod HIVDR analysis using amplification-refractory mutation system (ARMS)-PCR, Sanger sequencing, and longitudinal next-generation sequencing (NGS) to determine their profiles for the mutations K103N, Y181C, K65R, M184V, and T215F/Y. We processed 66 ART-naive HIV-1-positive patients with highly diverse subtypes that underlined the predominance of CRF02_AG and the increasing rate of F2 and other recombinant forms in Cameroon. We compared three resistance testing methods for 5 major mutation sites. Using Sanger sequencing, the overall prevalence of HIVDR mutations was 7.6% (5/66) and included all studied mutations except K65R. Comparing ARMS-PCR with Sanger sequencing as a reference, we obtained a sensitivity of 100% (5/5) and a specificity of 95% (58/61), caused by three false-positive calls with ARMS-PCR. For 32/66 samples, we obtained NGS data and we observed two additional mismatches made up of minority variants (7% and 18%) that might not be clinically relevant. Longitudinal NGS analyses revealed changes in HIVDR mutations in all five positive subjects that could not be attributed to treatment. In one of these cases, superinfection led to the temporary masking of a resistant virus. HIVDR mutations can be sensitively detected by ARMS-PCR and sequencing methods with comparable performances. Longitudinal changes in HIVDR mutations have to be considered even in the absence of treatment.
全球抗逆转录病毒疗法(ART)的强化可能导致接受治疗的患者以及未接受过ART治疗的患者中HIV耐药(HIVDR)突变率增加。对喀麦隆未接受过ART治疗的HIV-1感染患者进行了多方法HIVDR分析,采用扩增阻滞突变系统(ARMS)-PCR、桑格测序和纵向下一代测序(NGS)来确定他们K103N、Y181C、K65R、M184V和T215F/Y突变的情况。我们对66名未接受过ART治疗的HIV-1阳性患者进行了检测,这些患者具有高度多样的亚型,突出了喀麦隆CRF02_AG的优势以及F2和其他重组形式的增加率。我们比较了5个主要突变位点的三种耐药性检测方法。使用桑格测序,HIVDR突变的总体患病率为7.6%(5/66),包括除K65R以外的所有研究突变。将ARMS-PCR与作为参考的桑格测序进行比较,我们获得了100%(5/5)的灵敏度和95%(58/61)的特异性,ARMS-PCR出现了3例假阳性结果。对于32/66个样本,我们获得了NGS数据,并且观察到另外两个由少数变异体组成的错配(7%和18%),可能与临床无关。纵向NGS分析揭示了所有5名阳性受试者中HIVDR突变的变化,这些变化不能归因于治疗。在其中一个病例中,重复感染导致耐药病毒暂时被掩盖。ARMS-PCR和测序方法能够灵敏地检测HIVDR突变,性能相当。即使在没有治疗的情况下,也必须考虑HIVDR突变的纵向变化。